# CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma

> **NCT04237428** · NA · UNKNOWN · sponsor: **PersonGen BioTherapeutics (Suzhou) Co., Ltd.** · enrollment: 20 (estimated)

## Conditions studied

- Non Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** CD19 CAR-T cells infusion

## Key facts

- **NCT ID:** NCT04237428
- **Lead sponsor:** PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-31
- **Primary completion:** 2019-06-15
- **Final completion:** 2021-05-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04237428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04237428, "CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04237428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*